[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"content-doc-dcioa253669e":3},{"user":4,"document":8,"mainDocument":27,"columnUrl":29,"subscription":30,"footer":42,"text":80},{"isAuthenticated":5,"isAdmin":5,"displayName":6,"avatarUrl":6,"nid":6,"groupLevel":7},false,"",-10,{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":21,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},"dcioa253669e","礼来(LLY)“放下身段”，合作昔日冤家Hims(HIMS)，抢食自费减肥药市场","\u002Fdoc\u002Fdcioa253669e","col18178739ee","美股资讯","\u002Fcol\u002Fcol18178739ee","\u003Cp>\n\u003C\u002Fp>\u003Cp>\u003Cspan>美股投资网获悉，礼来(LLY)正与Hims & Hers Health Inc.(HIMS)展开合作，借助这家远程医疗公司庞大的客户群体，让其重磅减重药物覆盖更广泛的人群，从而提振包括旗下新型口服减重药Foundayo在内的药物销售。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>周五宣布的这项协议将使Hims平台的客户能够更方便地通过该平台以折扣价格直接获取礼来的减重药物。对礼来而言，这一合作提供了另一条触达愿意自费接受肥胖治疗患者的途径——这一群体在蓬勃发展的市场中正变得日益重要。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>“我们的目标是尽可能通过多元渠道提升药品可及性，摸清消费者的所在场景，在他们习惯的地方提供服务，”礼来美国及全球客户能力总裁伊利亚·尤法(Ilya Yuffa)在接受采访时表示。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>这份合作也标志着一次出人意料的和解此前，这家制药巨头曾因复方调配减重药相关问题，刻意和Hims这家远程医疗平台保持距离。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>这一转变反映出肥胖治疗市场正在发生更广泛的格局变化制药商正日益拥抱那些它们曾经试图遏制的远程医疗公司——这些公司此前销售其药物的廉价仿制版本。像Hims这样的平台已经建立起庞大的业务，服务于数百万自费接受治疗的人群，使其成为制药公司寻求触达传统保险渠道之外患者的宝贵合作伙伴。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>Hims首席执行官安德鲁・杜杜姆(Andrew Dudum)在采访中称“用户希望在这里获得诊疗服务、期待在这里就医，同时他们要求高品质、对消费者足够友好的体验。这也印证行业正在发生变革创新成果可以直达用户，省去繁琐中间环节。”\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>据尤法介绍，约30%至40%的患者通过远程医疗渠道获取肥胖药物。礼来已与多家远程医疗公司建立合作关系，包括Ro和Weight Watchers。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>今年早些时候，Hims宣布与Ozempic制造商诺和诺德(NVO)达成类似合作，结束了双方长达数月的不和。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>尤法表示，此前使用Hims的患者必须离开该远程医疗平台才能获取礼来的药物，这一流程阻碍了他们真正完成治疗。这意味着相对较少的Hims客户能够获得礼来的药物。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>如今，他们将能够更无缝地享受礼来为自费患者提供的折扣。礼来新推出的肥胖药片Foundayo最低剂量每月费用为149美元，而Zepbound起价为每月299美元。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>这一合作还可能扩大Foundayo的客户群体——该药物在截至10月的三个月季度销售额未达预期。不过，礼来近期已加大围绕该药物的营销活动，包括推出由玛莎·斯图尔特(Martha Stewart)出镜的新广告。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>对Hims而言，该协议开辟了另一条增长途径，因其正从复方GLP-1药物转向美国食品药品监督管理局(FDA)批准的药物，这有可能缓解与业内最具实力的制药商之一之间的紧张关系。礼来一直是对销售其药物未经批准版本的公司批评最为激烈的企业之一，誓言不与此类公司合作，甚至对部分企业提起诉讼。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>尤法强调，Hims从未售卖过礼来药品的复方调配版本，并且承诺未来也不会销售，这是礼来最终选择与其合作的关键考量。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>这一合作最终可能扩展至礼来的下一代疗法。杜杜姆表示，他预计未来几年双方将随着礼来产品组合的持续扩展而深化合作，尤其是围绕一款备受关注的肥胖药物retatrutide。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>“未来几年，我们将围绕所有即将推出的扩展产品展开合作，包括明年即将推出的retatrutide等药物以及该管线中的所有创新，”杜杜姆称。\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>最专业的美股资讯,推荐美股大数据 \u003Ca href=\"https:\u002F\u002FStockwe.com\u002F\">https:\u002F\u002FStockwe.com\u002F\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003Cspan>如何识别美股市场异常波动？美国机构主力资金买卖情况，出货和吸筹，使用美股投资网VIP会员，2008年成立于美国硅谷，由前纽约证券交易所分析师Ken创立，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化模型，建立了一个股市数据库 \u003Ca href=\"https:\u002F\u002FStockWe.com\u002F\">https:\u002F\u002FStockWe.com\u002F\u003C\u002Fa> 每天处理千万级股票数据：捕捉期权大单，实时主力资金流向、机构持仓变化、川普突发新闻，精准交易信号第一时间发到您手机APP！\u003C\u002Fspan>\u003C\u002Fp>\n\u003Cp>\u003C\u002Fp>","https:\u002F\u002Fwww.tradesmax.com\u002Fimages\u002Fa_Stock\u002FH\u002FHIMS\u002FHIMS.jpg","2026-11-06T13:52:36","2026.11.06","2026\u002F11\u002F06",51373,[22],"HIMS","Article",0,"免费","success",{"id":9,"fullTitle":10,"subTitle":6,"url":11,"columnId":12,"columnName":13,"columnUrl":14,"summary":6,"contentHtml":15,"mainContentHtml":6,"posterUrl":16,"createDate":17,"displayDate":18,"displayDateSlash":19,"pageviews":20,"tags":28,"hidden":5,"isSubContent":5,"replyDocOrTargetId":6,"contentType":23,"videoId":6,"liveVideoUrl":6,"useContentVideo":5,"duration":24,"price":24,"priceText":25,"priceBadgeText":25,"priceBadgeClass":26,"freeForMinGroupLevel":24,"redirectUrl":6,"readyToStream":5},[22],"\u002Fcol\u002Fstocknews",{"visible":5,"marketingHtml":31,"services":32,"recentDocuments":41},"\u003Cfigure class=\"image\">\u003Ca href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\" rel=\"noopener noreferrer\">\u003Cimg src=\"\u002Fimg\u002Fstockwewebfiles\u002Fweb-202408-stk\u002F1586109431mceclip0.jpg\">\u003C\u002Fa>\u003C\u002Ffigure>\u003Cdiv class=\"text-center\">\u003Ch2 class=\"card-title mx-auto\">\u003Cbr>\u003Ca rel=\"noopener noreferrer\" href=\"https:\u002F\u002Fstockwe.com\u002Fdoc\u002Fdcio537efad5\">案例介绍：英伟达深度研究报告\u003C\u002Fa>\u003C\u002Fh2>\u003C\u002Fdiv>",[33,37],{"productId":34,"serviceName":35,"priceText":36},"prod_PPxdDdK87QaiLv","月付","$12.95美元",{"productId":38,"serviceName":39,"priceText":40},"prod_PPxeMs3bix1da5","年付","$149.00美元",[],{"links":43,"images":71,"summaryHtml":76,"aboutTitle":77,"aboutHtml":78,"copyrightHtml":79},[44,47,50,53,56,59,62,65,68],{"label":45,"url":46},"深度报告","\u002Fcol\u002FdepthReport",{"label":48,"url":49},"VIP会员","\u002Fvip",{"label":51,"url":52},"期权推荐","\u002FOption",{"label":54,"url":55},"低价暴涨股","\u002FPenny",{"label":57,"url":58},"AI智能体","\u002FAiAgent",{"label":60,"url":61},"常见问题","https:\u002F\u002Fstockwe.com\u002FFAQ",{"label":63,"url":64},"美股课程","\u002Fcol\u002Fvideos",{"label":66,"url":67},"免责声明","\u002Fdisclaimer",{"label":69,"url":70},"联系我们","\u002FContactUs",[72,73,74,75],"\u002Fimages\u002Ffooter\u002Ffooter-1-wechat.gif?v=20260930c","\u002Fimages\u002Ffooter\u002Ffooter-2-telegram.png?v=20260930c","\u002Fimages\u002Ffooter\u002Ffooter-3-whatsapp.png?v=20260930c","\u002Fimages\u002Ffooter\u002Ffooter-4-line.png?v=20260930c","邮箱: buy@TradesMax.com 美国电话 626-378-3637","公司介绍","\u003Cp class=\"MsoNormal\">美股大数据 \u003Ca href=\"https:\u002F\u002Fstockwe.com\" rel=\"noopener\">StockWe.com\u003C\u002Fa> 是一个美国领先的金融和美股信息大数据提供商，紧盯华尔街金融市场和行情，2008年成立于美国硅谷，创始人是前纽约证券交易所资深分析师Ken，联合多位摩根斯坦利分析师，谷歌 Meta工程师利用AI和大数据，配合十多年美股实战经验和业内量化交易模型，每天处理海量股票数据：挖掘潜力大牛股，捕捉期权异动大单，实时主力资金流向、机构持仓变化、川普突发新闻，美股买卖信号第一时间发到您手机APP。\u003C\u002Fp>","专业美股投资者都在这里",{"loading":81,"search":82,"searchPlaceholder":82,"hotContent":83,"draft":84,"noData":85,"searchNoData":86,"courseContent":87,"more":88,"buyNow":89,"subscribeNow":90,"encoding":91,"paidContent":92},"Loading...","搜索","热门内容","草稿","目前没有任何内容公布","当前检索内容没有数据","课程内容","更多","立即购买后观看","- 立即订阅 -","视频编码中...","付费内容"]